Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 400 for your search:
Cancer Type/Condition:
Non-Hodgkin lymphoma, adult
Stage/Subtype:
aggressive, recurrent adult non-Hodgkin lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
3.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
4.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
5.
Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1813.00
, 5666, NCT00075478
6.
Phase III Randomized Study of Salvage Chemotherapy Comprising Dexamethasone, Cisplatin, and Gemcitabine Versus a Standard Platinum-Based Regimen (Dexamethasone, Cisplatin, and High-Dose Cytarabine) Before Autologous Stem Cell Transplantation and With or Without Maintenance Rituximab in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
CAN-NCIC-LY12
, NCT00078949, LY12
7.
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CCBX001-049
, NCT00078598
8.
Stem Cell Transplant for Hematological Malignancy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
54 and under
Sponsor:
Other
Protocol IDs:
0107M05202
, MT2001-02, NCT00176930
9.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
NHLBI
Protocol IDs:
384
, BMT CTN 0401, U01 HL069294-05, NCT00329030
10.
Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
NCI
Protocol IDs:
CBMTG-0601
, NCT00438958
11.
Phase III Randomized Study of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Diffuse Large Cell Lymphoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0681
, MC0681, NCT00566228
12.
Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
NCI, Other
Protocol IDs:
09-073
, NCT00928018
13.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases or Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
14.
Phase I/II Study of Autologous Peripheral Blood Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic PBSC Transplantation in Patients With Refractory or Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1409.00
, 4903, NCI-G00-1776, NCT00005803
15.
Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-1803.00
, 5606, NCT00068718
16.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
17.
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
ID01-233
, NCT00048737
18.
Phase I/II Pilot Study of Flavopiridol in Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
OSU-04100
, OSU-2005C0006, NCI-7002, 7002, NCT00112723
19.
Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
20.
Phase I/II Randomized Study of Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Patients With Relapsed or Refractory Indolent B-Cell Lymphoproliferative Disorders or Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-05103
, NCT00295932
21.
Phase I/II Study of Gemcitabine Hydrochloride and Bortezomib in Patients With Relapsed or Refractory Aggressive B- or T-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-04H4
, NU-1346-011, NU-200411-0379, MILLENNIUM-NU-04H4, LILLY-NU-04H4, VEL-03-082, NCT00290706
22.
Phase I/II Study of Fenretinide and Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
WU-6071
, 6071, FHCRC-6071, NCI-6957, 6957, UWCC-UW-6071, UWCC-06-0644-H/A, NCT00288067
23.
A Study of SB-743921 in Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CY 2121
, NCT00343564
24.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
25.
Phase I/II Study of ABT-263 in Patients With Relapsed or Refractory T-cell or B-cell Lymphoid Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0006
, NCI-P7060, ABBOTT-M06-814, NCT00408811
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
